Baumann Confirmed As Bayer's New CEO
This article was originally published in Scrip
Executive Summary
Bayer has confirmed that its head of strategy and portfolio management, Werner Baumann, is to be its new CEO effective May 1, 2016. Current CEO Marijn Dekkers has proposed that his contract be dissolved on April 30 following the annual stockholders meeting. His contract was originally set to run until Dec. 31, 2016. Dekkers had signaled his intention to step down as CEO this year back in 2014. Baumann has been with Bayer since 1988 in a variety of roles including chief financial officer, and was credited with playing a key role in the integration of Schering following the 2006 merger with Bayer. His name had been widely linked with the top job at Bayer since Olivier Brandicourt's departure to head up Sanofi a year ago.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.